Cipla Medpro inks marketing pact with Teva for South Africa

Cipla Medpro (a part of Cipla Ltd located in South Africa), through its subsidiary company Medpro Pharmaceutica (Pty) Ltd, has entered into a collaboration with Teva Pharmaceuticals (Pty) Ltd, an affiliate of Teva Pharmaceutical Industries Ltd (Teva) - the largest generic pharmaceutical manufacturer in the world with a presence in about 60 countries and approximately 45,000 dedicated employees worldwide. The collaboration is restricted to the territory of South Africa.
 
The collaboration is a sales and distribution arrangement whereby Cipla Medpro will exclusively market Teva’s broad pharmaceutical product portfolio in South Africa.
 
“This collaboration is highly complementary and aligns strongly with our philosophy of providing South Africans with access to a broader range of affordable medicines,” said Paul Miller, Chief Executive Officer of Cipla Medpro.
 
The collaboration with Teva in South Africa will focus on the therapeutic areas such as oncology, central nervous system, women’s health, cardiovascular, ophthalmology and other specialty products.
 
“Cipla believes that the collaboration with Teva reaffirms its commitment to advancing healthcare for all South Africans,” said Subhanu Saxena, Managing Director and Global Chief Executive Officer of Cipla Limited.
 
The collaboration is subject to approval by the Competition Commission of South Africa.